media – Page 19 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Climbing the “Mount Everest of Brain-Computer” requires a complete logistical support system to support long-term expeditions.

“The industry is thinking about how to make machines understand people’s minds, while we are exploring how to make the brain understand machines,” said Dr. Liu Bing, founder of Mindtrix, at the 2026 Yabuli Forum, explaining their work. Currently, the global competition in brain-computer interfaces focuses on “reading” brain signals to achieve cool applications such as thought control. Mindtrix, however, focuses on feedback-based motor control based on “brain-computer dual learning” and visual reconstruction based on closed-loop large-scale stimulation. Dr. Liu Bing defines this as “reverse engineering”—they are tackling “writing” brain-computer interfaces, aiming to input precise electrical signal maps into the visual cortex of the brain to restore sight to those who are completely blind. These two directions outline two completely different philosophies of innovation. The former iterates and optimizes along a relatively clear path, while the latter attempts to establish a completely new basic communication protocol at the boundary between ...
- Source: drugdu
- 102
- March 24, 2026
Pfizer’s potential “blockbuster” drug achieves success in Phase 2 clinical trials

Recently, Pfizer announced positive results from its proprietary, highly selective CDK4 inhibitor, Atirmociclib, in the Phase 2 clinical trial (FOURLIGHT-1) for the treatment of previously treated HR+/HER2- advanced or metastatic breast cancer. Based on this positive result, Pfizer believes that Atirmociclib has the potential to become the next blockbuster product in breast cancer treatment , and also gives confidence to other CDK4 inhibitors in development. 01 Next-generation CDK inhibitors Breast cancer is a common malignant tumor in women, most of which belong to the hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2-) subtype. The rise of CDK4/6 inhibitors has brought a breakthrough in precision treatment of this subtype of breast cancer, shifting the treatment modality for HR+/HER2- breast cancer patients from single-drug endocrine therapy to a combination of endocrine and targeted therapy. Currently, CDK4/6 inhibitors combined with endocrine therapy have become the standard treatment for HR+/HER2- advanced breast ...
- Source: drugdu
- 177
- March 24, 2026
Hong Kong Medical and Healthcare Fair

Organiser：Hong Kong Trade Development Council Time：May 11 – May 13, 2026 Address：No.1 Expo Drive, Wan Chai District, Hong Kong Exhibition hall：Hong Kong Convention and Exhibition Centre Product range: Construction technology and hospital furniture, dental equipment and supplies, home medical products, hospital instruments, laboratory equipment, production and design solutions, medical supplies and consumables, physical therapy instruments and supplies exhibition area, rehabilitation and elderly care products, medical beauty instruments and supplies, technology hub, business services and publications About Hong Kong Medical and Healthcare Fair： The Hong Kong International Medical and Healthcare Fair is an event where international medical and healthcare professionals can keep abreast of the latest market trends. It provides an ideal platform for industry insiders to learn about the latest developments in the medical sector and forge close connections within the industry.
- Source: drugdu
- 124
- March 24, 2026
Eli Lilly invests $3 billion in China

Recently, Eli Lilly announced plans to invest a total of $ 3 billion over the next ten years to fully expand its supply chain capacity in China . According to the plan, the $3 billion investment will adopt a dual-track model of ” internal expansion + external cooperation “: on the one hand, it will leverage the technological and talent advantages of the Suzhou factory to strengthen the synergistic production capacity of incretin injection; on the other hand, it will add oral solid dosage form production capacity in Beijing and cooperate with multiple local production partners to release incremental production capacity. As a key move in this round of investment, Eli Lilly also announced a strategic partnership with Kanglong Chemical , a leading domestic CDMO company , on the same day. The initial investment of $200 million will support Kanglong’s technological capabilities, with plans to gradually expand the scale as ...
- Source: drugdu
- 114
- March 23, 2026
Medtronic invests $550 million in neurointerventional surgery.

According to recent foreign media reports, global medical device giant Medtronic announced that it will acquire Scientia Vascular for $550 million to strengthen its stroke treatment portfolio. Image source: Fierce Biotech Scientia Vascular is a company specializing in the manufacture of specialized guidewires, microcatheters, and access products for reaching complex blood clots deep in the brain. According to data from PharmNet Medical Devices, the company has already launched 16 products in the United States. In 2021, Scientia completed a $50 million funding round, which the company reportedly used to accelerate sales, marketing, and new product development in its core neurovascular stroke market, as well as peripheral vascular and interventional oncology-related markets. Scientia’s process involves etching slots into a solid nickel-titanium alloy tube to form a closed loop and interconnected beams—allowing the guidewire to effectively transmit torque while meandering through the brain’s small, winding blood vessels. The company states that this ...
- Source: drugdu
- 101
- March 23, 2026
Roche’s blockbuster new drug receives approval for a new indication, becoming the world’s first to do so.

Diffuse large B-cell lymphoma ( DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), accounting for 31%–34% of NHL cases globally and 45.8% in China. The incidence rate increases with age. Even after first-line treatment, 30%–40% of DLBCL patients face relapse or refractory outcomes, resulting in a poor prognosis and challenging survival.On March 13, 2026, according to the latest announcement on the official website of the National Medical Products Administration (NMPA) of China , Roche (China) Investment Co., Ltd. ‘s application for a new indication for injectable veportuzumab has been approved for marketing in China . According to Roche’s press release, the indication is: this product in combination with rituximab , gemcitabine, and oxaliplatin (Pola-R-GemOx) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not suitable for hematopoietic stem cell transplantation. Public information shows that vedotin (Urithema®, Polivy®) is an antibody-drug conjugate (ADC) targeting ...
- Source: drugdu
- 93
- March 23, 2026
Lunan Pharmaceutical’s carfilzomib API receives dual approval from China and the US for market launch.

Recently, Shandong New Era Pharmaceutical Co., Ltd., a subsidiary of Lunan Pharmaceutical Group, received a marketing authorization notice for carfilzomib issued by the National Medical Products Administration . This approval further enriches the company’s anti-tumor active pharmaceutical ingredient (API) product line. The product, manufactured using the same production line and process, has also been submitted for US approval, providing a better option for domestic and international pharmaceutical formulation customers. Carfilzomib, as a second-generation proteasome inhibitor, exerts significant anti-proliferative and pro-apoptotic effects on tumor cells by irreversibly binding to the 20S proteasome active site. Its high selectivity results in a lower risk of neurotoxicity, and it is well tolerated by patients. Clinical data confirm that it has a reliable safety advantage in the treatment of multiple myeloma and is the preferred clinical option. Established in 2017, the International Drug R&D Center adheres to an international strategy of “based in China, radiating ...
- Source: drugdu
- 118
- March 23, 2026
A major men’s health product with sales exceeding 6 billion yuan! Kelun Pharmaceutical secures the first nationwide generic version of its new dosage form.

Kelun Pharmaceutical’s oral disintegrating film for sildenafil citrate (50mg/25mg), submitted as a Class 3 chemical drug, has been officially approved for marketing. This not only means that the first company in China to launch this new dosage form of the drug, but also that Kelun Pharmaceutical has become the “first generic manufacturer of sildenafil citrate oral disintegrating film in China” with this approval, and is regarded as the first company to pass the consistency evaluation. In the fiercely competitive market of andrology drugs, sildenafil, a “super product” with its own built-in traffic, has always been a battleground for companies. According to data from PharmNet, the domestic sildenafil market has maintained a high scale in recent years, with total sales reaching 6.6 billion yuan in 2023 and remaining at a massive 6.3 billion yuan in 2024. Faced with such a huge market worth tens of billions of yuan for treating erectile ...
- Source: drugdu
- 109
- March 23, 2026
GE Healthcare completes major acquisition for 15.87 billion yuan!

According to recent foreign media reports, GE Healthcare announced that it has completed the previously announced acquisition of Inteleraad for $2.3 billion (approximately RMB 15.87 billion). GE Healthcare officially announced last November that it would acquire Inteleraad for $2.3 billion. Inteleraad, founded in 1999, reportedly possesses imaging software and digital enterprise workflow solutions, and has a significant presence in the outpatient healthcare field. According to data from Yaozhi Medical Devices, Inteleraad currently has several marketed products in the United States. Of particular note is Inteleraad’s ability to provide cloud-first products designed specifically for radiology and cardiology, covering both inpatient and outpatient medical environments. This is a major reason why GE Healthcare was willing to acquire Inteleraad for a hefty sum. With the completion of the transaction, Intelerad will operate as part of GE Healthcare’s medical imaging business, and GE Healthcare expects Intelerad to continue serving enterprise imaging solutions customers in ...
- Source: drugdu
- 94
- March 23, 2026
Hengrui’s innovative drug, Likang Kepan fumarate capsules, has had its marketing application accepted for the treatment of paroxysmal nocturnal hemoglobinuria.

Recently, Chengdu Shengdi Pharmaceutical Co., Ltd., a subsidiary of Hengrui Medicine, received an “Acceptance Notice” from the National Medical Products Administration. The drug application for marketing authorization of the company’s independently developed Class 1 new drug, Likang Kepan Capsules of Fumarate, has been accepted. The indication is: treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who still have anemia after previous treatment with C5 complement inhibitors. This is expected to bring new options for the treatment of this rare disease. Research on HRS-5965-302 This application for market approval is based on a multicenter, single-arm, open-label phase III clinical trial evaluating the efficacy and safety of Likang Kepan fumarate capsules (development code: HRS-5965) in PNH patients who still have anemia after 6 months of stable treatment with C5 complement inhibitors. The study was jointly led by Professor Shi Jun of the Institute of Hematology and Blood Diseases Hospital of Chinese ...
- Source: drugdu
- 95
- March 23, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.